Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2022 | Long-term clinical results of TPS in Alzheimer’s disease

Lars Wojtecki, MD, PhD, Institute of Clinical Neuroscience and Medical Psychology, University Düsseldorf, Düsseldorf, Germany, discusses the short and long-term clinical results of transcranial pulse stimulation (TPS) in Alzheimer’s disease. After one year, results show stable effects on cognitive measures after TPS. Still, the effect is not yet significant; this may be because the study was underpowered since only a small group of patients were available for long-term follow-up. The following steps of this investigation will be to finalize the long-term follow-up with the entire group of patients. Additionally, the results from the Austrian prospective, placebo-controlled clinical trial are highly anticipated as they will provide a better understanding of the effect of TPS on Alzheimer’s disease. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.


Grants/Institutional Support: Hilde Ulrichs Stiftung für Parkinsonforschung, ParkinsonFonds Deutschland, BMBF/ERA-NETNEURON, DFG Forschergruppe (FOR1328), Deutsche Parkinson Vereinigung (DPV), Forschungskommission, Medizinische Fakultät, HHU Düsseldorf, UCB; Medtronic, UCB, Teva, Allergan, Merz, Abbvie, Roche, Bial, Merck, Novartis, Desitin, Spectrum;
Honorary/Travel Grants/Consultancy: TEVA, UCB Schwarz, Desitin, Medtronic, Abbott/Abbvie, MEDA, Boehringer I, Storz Medical, Kyowa Kirin, Guidepoint, Merck, Merz, Synergia, BIAL, Zambon, Sapio Life, STADA, Inomed, Vertanical;
Stock Ownership: BioNTech.